Welcome to our dedicated page for Research Solutions SEC filings (Ticker: RSSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Research Solutions, Inc. filings document a Nevada operating company with common stock listed on The Nasdaq Capital Market under the symbol RSSS. The company’s regulatory disclosures cover its AI-powered research workflow business, including SaaS platform subscriptions and transaction-based electronic article delivery.
Recent filings include Form 8-K reports for quarterly and fiscal-year operating results, as well as officer-change disclosures. Proxy materials and annual meeting filings document board elections, auditor ratification, advisory votes on executive compensation, voting mechanics, and stockholder meeting results. The filings also identify the company’s registered common stock, governance framework, and public-company reporting obligations.
Research Solutions, Inc. reported improved profitability for the quarter and nine months ended March 31, 2026. Quarterly revenue was $12.1M, down 4.3% year over year, but net income rose to $0.86M from $0.22M as operating expenses declined and gross margin reached 51.7%.
For the nine months, revenue was $36.2M versus $36.6M a year earlier, while net income swung to $2.16M from a loss of $1.09M. Platforms revenue grew as Transactions declined, cash stood at $12.1M with no borrowings on the $0.5M credit line, and stockholders’ equity increased to $19.1M.
Research Solutions, Inc. reported fiscal third quarter 2026 results with net income of $860,000, or $0.03 per diluted share, and Adjusted EBITDA of $1.6 million, up 14% from a year earlier. Total revenue was $12.1 million, down 4.3%, as growth in higher‑margin Platform subscriptions was offset by lower Transactions revenue.
Platform subscription revenue rose to $5.2 million, a 6.6% increase, and annual recurring revenue reached $22.1 million, up 8.5% year over year. Total gross margin improved to 51.7%, while operating expenses declined to $5.2 million, supporting stronger profitability. For the nine months ended March 31, 2026, the company generated net income of $2.2 million versus a loss in the prior period, and ended the quarter with cash and cash equivalents of $12.1 million.
Research Solutions, Inc. shareholders Poplar Point entities and Jad Fakhry filed an amendment to a Schedule 13G reporting shared beneficial ownership of common stock. The filing states 2,329,374 shares for Poplar Point Capital Management LLC and Mr. Fakhry, representing 7.08% of the class, and 1,317,872 shares for Poplar Point Capital Partners and related entities, representing 4.01%, based on 32,905,476 shares outstanding as of December 31, 2025.
The filing is a joint statement describing voting and dispositive powers (shared, not sole) and includes a joint filing agreement signed by Jad Fakhry on 05/11/2026.
Cohen Sefton reported acquisition or exercise transactions in this Form 4 filing.
Research Solutions, Inc. Chief Revenue Officer Cohen Sefton received a grant of 80,000 shares of restricted common stock valued at $2.29 per share as equity compensation. One‑third of these restricted stock awards vest on March 18, 2027, with the remainder vesting quarterly beginning March 31, 2027. Following this award, Sefton directly holds 359,933 shares of common stock.
Research Solutions, Inc. reported a return to profitability for the quarter ended December 31, 2025. Total revenue was $11.8 million, down slightly from $11.9 million a year earlier, as growth in software subscriptions offset weaker transactional sales.
Platforms revenue grew to $5.2 million, up 13.6%, while Transactions revenue declined 10.2% to $6.6 million. Gross profit increased to $6.2 million, expanding gross margin to 52.4% from 48.9%, helped by lower content costs.
Operating income rose sharply to $0.7 million from $0.1 million, with lower general and administrative and stock-based compensation expenses. Net income was $0.5 million, or $0.02 per diluted share, compared with a loss of $2.0 million, largely reflecting a much smaller non-cash loss on the Scite earnout revaluation.
For the six months, revenue was $24.1 million, up 0.6%, with Platforms up 15.8% and Transactions down 8.4%. Net income reached $1.3 million versus a $1.3 million loss. The company generated $2.5 million of operating cash flow and ended the period with $12.3 million in cash and no borrowings on its $0.5 million credit line.
Research Solutions, Inc. reported a profitable fiscal second quarter 2026, reversing a prior-year loss. Net income was $547,000, or $0.02 per diluted share, compared with a net loss of $2.0 million a year earlier. Adjusted EBITDA rose to $1.3 million, up 35.6%.
Total revenue was $11.8 million, down 1.0%, as strong growth in higher-margin Platform subscriptions offset weaker Transaction revenue. Platform revenue grew 13.6% to $5.2 million, and total annual recurring revenue reached $21.8 million, up 13.9% year-over-year. Gross margin expanded to 52.4%, while operating expenses declined 5.1%, supporting improved profitability and cash generation.
A director of Research Solutions, Inc. reported receiving an option to purchase 50,000 shares of the company’s common stock. The stock option was granted on 11/12/2025 with an exercise price of $3.07 per share and an expiration date of 11/11/2035. The option was reported as directly owned and carried a price of $0 at grant, indicating it was an award rather than a market purchase.
According to the vesting terms, one-third of the options vest on November 12, 2026, and one-twelfth of the options vest on the last day of each quarter beginning December 31, 2026 until fully vested. This creates a multi‑year vesting schedule that ties the director’s potential ownership to ongoing service and future company performance.
Research Solutions, Inc. reported that one of its directors exercised stock options to acquire 75,000 shares of common stock on 11/12/2025 at an exercise price of $0.7 per share. Following this transaction, the director directly beneficially owns 484,608 shares of the company’s common stock.
On the same date, the director was granted a new option to purchase 50,000 shares of common stock at an exercise price of $3.07 per share, expiring on 11/11/2035. According to the vesting schedule, one third of these options vest on November 12, 2026 and one twelfth vest on the last day of each quarter beginning December 31, 2026 until fully vested, while the previously held option for 75,000 shares at $0.7 was fully exercised and now shows 0 remaining.
Research Solutions, Inc. (RSSS) director Form 4 reports an option exercise and share acquisition. On 11/17/2025, the reporting director exercised an option to purchase 150,000 shares of common stock at an exercise price of $0.70 per share, coded as transaction type "M" (option exercise). After this transaction, the director beneficially owned 318,500 shares of common stock directly and 75,000 shares indirectly through an IRA. A corresponding entry in the derivative table shows the option to purchase 150,000 shares at $0.70, originally exercisable on 12/04/2015 and expiring on 12/03/2025, with zero derivative securities remaining following this exercise.
Research Solutions, Inc. (RSSS) reported that one of its directors received an option grant for 60,000 shares of common stock on 11/12/2025 at an exercise price of $3.07 per share. These stock options expire on 11/11/2035, giving the holder a long window to buy shares at that price if they choose.
The options vest over time. One-third of the grant vests on 11/12/2026, and the remaining two-thirds vest in equal installments on the last day of each quarter beginning 12/31/2026 until fully vested. Following this transaction, the reporting person directly holds 60,000 derivative securities (stock options) tied to Research Solutions common stock.